You are here:

ropinirole prolonged release (Requip XL)

Advice

Following an abbreviated submission

ropinirole 2 mg, 4 mg, 8 mg prolonged-release tablets (Requip® XL) are accepted for use in NHS Scotland for the treatment of idiopathic Parkinson’s disease in patients already taking ropinirole immediate release tablets and in whom adequate symptomatic control has been established.

Substitution of ropinirole prolonged release tablets for ropinirole immediate release tablets may be used as:

Monotherapy, alone (without levodopa) in idiopathic Parkinson’s disease,

or as:

Adjunctive therapy in addition to levodopa to control ‘on-off’ fluctuations which might permit a reduction in the total daily dose of levodopa.

Substitution of prolonged-release ropinirole for ropinirole immediate release tablets should be supervised by appropriate specialists in Parkinson’s disease.

Drug Details

Drug Name: ropinirole prolonged release (Requip XL)
SMC Drug ID: 491/08
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Treatment of idiopathic Parkinson's Disease
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 September 2008

Back